Scientists discover new molecules that kill cancer cells and protect healthy cells
Research in mice suggests
molecules could treat cervical, breast, ovarian, and lung cancers
Research in mice suggests molecules could treat cervical, breast, ovarian, and lung cancers
A new family of molecules that kill cancer cells and protect healthy cells could be used to treat a number of different cancers, including cervical, breast, ovarian and lung cancers. Research published in EBioMedicine shows that as well as targeting and killing cancer cells, the molecules generate a protective effect against toxic chemicals in healthy cells.
Cells can become cancerous when their DNA is damaged. Many different things can cause DNA damage, including smoking, chemicals and radiation; understanding exactly what happens at the point of DNA damage can help scientists develop new cancer treatments. By studying this mechanism, researchers from the University of Waterloo in Canada could identify new molecules that selectively target cancer cells.
The researchers studied the process of DNA damage using a sort of molecular filming technique called femtosecond time-resolved laser spectroscopy. The technique is like a high-speed camera, which uses two pulses of light: one to start a reaction, and the other to monitor the way the molecules react. This technique let researchers watch how molecules interact in real-time, revealing how cells become cancerous.
Researchers have been using femtosecond laser spectroscopy to study biological molecules for decades, in fields called femtochemistry and femtobiology. More recently, this technique was fused with molecular biology and cell biology techniques to advance our understanding of human diseases, notably cancer, and how their treatments work. This potential new field is being dubbed femtomedicine (FMD).
“We know DNA damage is the initial and crucial step in the development of cancer,” said Professor Qing-Bin Lu, lead author of the study from the University of Waterloo, Canada. “With the FMD approach we can go back to the very beginning to find out what causes DNA damage in the first place, then mutation, then cancer. FMD is promising as an efficient, economical and rational approach for discovering new drugs, as it can save resources required to synthesize and screen a large library of compounds.”
Taking advantage of the FMD approach, Professor Lu and his colleagues discovered a new family of molecules called nonplatinum-based halogenated molecules, or FMD compounds. These are similar to cisplatin – a drug used to treat ovarian, testicular, lung, brain and other cancers. However, while cisplatin is highly toxic, the new FMD compounds are not harmful to normal cells.
When the FMD compounds enter a cancer cell, they react strongly and form reactive radicals, which cause the cell to kill itself. When the FMD compounds enter a healthy cell, the cell starts to increase the amount of a protective molecule called glutathione (GSH) in the cell. This protects the cell against chemical toxins, so it is not damaged.
The researchers tested the molecules on human cells and in mice, and found very consistent results. They treated human cells – various normal and cancer cells – with the FMD compounds and tested them to see whether the cells were killed. They also tested the levels of GSH in the cells, revealing that the amount of protective molecule increased in the normal cells, while it decreased in cancer cells.
They then tested the FMD compounds on a range of tumors in mice, representing cervical, ovarian, breast and lung cancers. They measured the extent to which the FMD compounds slowed down tumor growth, and found it was effective at slowing or halting the growth of all tumors.
“We’re very excited about our discovery; we can see that the FMD compounds are just as effective as cisplatin in mice but without being toxic,” said Professor Lu. “We believe that it could potentially be used to treat a very wide rage of cancers, without making patients suffer the toxic side effects that some existing drugs have.”
“We want this discovery to help patients, and we plan to move it into clinical trials as soon as possible,” added Professor Lu.
“In Vitro and In Vivo Studies of Non-Platinum-Based Halogenated Compounds as Potent Antitumor Agents for Natural Targeted Chemotherapy of Cancers” by Qing-Bin Lu, Qin-Rong Zhang, Ning Ou, Chun-Rong Wang and Jenny Warrington (doi: 10.1016/j.ebiom.2015.04.011). The article appears in online EBioMedicine, published by Elsevier.
The article is available as open access paper:
For more information or to schedule an interview with the authors, contact Elsevier’s Newsroom at firstname.lastname@example.org or +31 20 4853564
The effective translation of insights gained from biomedical research into improved human health is a global priority. To this end, Elsevier has looked to the leadership of its two leading brands, Cell and The Lancet, to guide the launch of a new comprehensive, online-only open access, rapid publication Elsevier journal, EBioMedicine, focused on forming a community that spans this interface and creates a valuable opportunity for dialogue and collaboration between their respective audiences. As the communities that border this interface are large and diverse, the scope of EBioMedicine covers the entire breadth of translational and clinical research within all disciplines of life and health sciences, ranging from basic science to clinical and public/global health science. The journal is committed to facilitating and incentivizing a robust and successful pipeline for improved human health globally (www.ebiomedicine.com).
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com